Call for Papers  

Article Details

CsHscB Derived from a Liver Fluke <i>Clonorchis sinensis</i> Ameliorates Cholestatic Hepatic Fibrosis in a Mouse Model of Sclerosing Cholangitis

[ Vol. 24 , Issue. 4 ]


Qian Yu, Stephane Koda, Na Xu, Jing Li, Jian-Ling Wang, Man Liu, Ji-Xin Liu, Yu Zhang, Hui-Min Yang, Bei-Bei Zhang, Xiang-Yang Li, Xiao-Cui Li, Ren-Xian Tang, Kui-Yang Zheng* and Chao Yan*   Pages 505 - 515 ( 11 )


<p>Background: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammatory fibrosis usually involving the whole biliary tree. However, there are very limited treatment options to treat this disease. Our previous study found a lipid-protein rCsHscB from a liver fluke - <i>Clonorchis sinensis</i>, which had full capacities of immune regulation. Therefore, we investigated the role of rCsHscB in a mouse model of sclerosing cholangitis induced by xenobiotic 3,5- diethoxycarbonyl-1,4-dihydrocollidine (DDC) to explore whether this protein had potential therapeutic value for PSC. <p> Methods: Mice were fed 0.1% DDC for 4 weeks and treated with CsHscB (30 μg/mouse, intraperitoneal injection, once every 3 days); the control group was given an equal amount of PBS or CsHscB under normal diet conditions. All the mice were sacrificed at 4 weeks for the evaluation of biliary proliferation, fibrosis, and inflammation. <p> Results: rCsHscB treatment attenuated DDC-induced liver congestion and enlargement and significantly decreased the upregulation of serum AST and ALT levels. The administration of rCsHscB to DDC-fed mice significantly decreased cholangiocyte proliferation and pro-inflammatory cytokine production compared to mice fed with DDC alone. Also, rCsHscB treatment showed a decreased expression of &#945;-SMA in the liver and other markers of liver fibrosis (Masson staining, Hydroxyproline content, and collagen deposit). More interestingly, DDC-fed mice treated with rCsHscB showed a significant up-regulation of PPAR-&#947; expression, which was similar to control mice, indicating the involvement of PPAR-&#947; signaling in the protective action of rCsHscB. <p> Conclusion: Overall, our data show that rCsHscB attenuates the progression of cholestatic fibrosis induced by DDC and supports the potential for manipulating the parasite-derived molecule to treat certain immune-mediated disorders.</p>


Protein CsHscB, Clonorchis sinensis, DDC, Cholestatic liver fibrosis, PPAR-γ, Immune regulation.


Read Full-Text article